Skip to main content
Benaroya Research Institute

Main navigation

  • About BRI
    • Leadership
    • Faculty
    • Administrative Leaders
    • Together We Discover
    • Contact Us
  • Our Research
    • Centers of Discovery
      • Fundamental Immunology
      • Translational Immunology
      • Interventional Immunology
      • Systems Immunology
        • Bioinformatics at BRI
    • Labs
    • Biorepositories
      • Be a Part of BRI Research
    • Clinical Research
      • Allergies & Asthma Clinical Research
    • Core Labs
      • Cell And Tissue Analysis Group
      • Genomics Core
      • Human Immunophenotyping Core
      • Protein and Tetramer Core
        • Protein & Tetramer Core Ordering
    • Immune Tolerance Network
    • Scientific Publications
    • Scientific Meetings at BRI
      • Asthma Research Symposium
      • BRI Immunology Symposium: New Horizons in Immunity and Disease
      • Cross Autoimmunity Prevention Symposium
  • Collaborations with BRI
    • Opportunities for Collaboration
    • Technology Available for Licensing
  • News
    • Press Releases
  • Support our Research
    • Donate Now
    • BRI Events
      • BRI Open House
      • Immunology to Change Lives

Utility Menu

  • Immunology Learning Center
  • Autoimmune Life Blog
  • Careers
  • Clinical Research at VMMC
  • Donate
  • Search
    • Mar 2025

      Proteomic Analyses in COVID-19-Associated Secondary Hemophagocytic Lymphohistiocytosis.

      Crit Care Explor
      Canny SP, Stanaway IB, Holton SE, Mitchem M, O'Rourke AR, Pribitzer S, Baxter SK, Wurfel MM, Malhotra U, Buckner JH, Bhatraju PK, Morrell ED, Speake C, Mikacenic C, Hamerman JA
    • Aug 2024

      Identification of biomarkers for COVID-19 associated secondary hemophagocytic lymphohistiocytosis.

      bioRxiv
      Canny SP, Stanaway IB, Holton SE, Mitchem M, O'Rourke AR, Pribitzer S, Baxter SK, Wurfel MM, Malhotra U, Buckner JH, Bhatraju PK, Morrell ED, Speake C, Mikacenic C, Hamerman JA
    • Aug 2024

      Mediators of monocyte chemotaxis and matrix remodeling are associated with mortality and pulmonary fibroproliferation in patients with severe COVID-19.

      PLoS One
      Holton SE, Mitchem M, Chalian H, Pipavath S, Morrell ED, Bhatraju PK, Hamerman JA, Speake C, Malhotra U, Wurfel MM, Ziegler SE, Mikacenic C
    • Jul 2024

      PD-L1 and PD-1 Are Associated with Clinical Outcomes and Alveolar Immune Cell Activation in ARDS.

      Am J Respir Cell Mol Biol
      Morrell ED, Holton SE, Wiedeman A, Kosamo S, Mitchem MA, Dmyterko V, Franklin Z, Garay A, Stanaway IB, Liu T, Sathe NA, Mabrey FL, Stapleton RD, Malhotra U, Speake C, Hamerman JA, Pipavath S, Evans L, Bhatraju PK, Long SA, Wurfel MM, Mikacenic C
    • Jun 2023

      Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumonia.

      EBioMedicine
      Mabrey FL, Nian H, Yu C, Barnes EM, Malhotra U, Mikacenic C, Goldstein J, O'Mahony DS, Garcia-Diaz J, Finn P, Voelker K, Morrell ED, Self WH, Becker PM, Martin TR, Wurfel MM
    • May 2023

      Mediators of monocyte chemotaxis and matrix remodeling are associated with the development of fibrosis in patients with COVID-19.

      medRxiv
      Holton SE, Mitchem M, Pipavath S, Morrell ED, Bhatraju PK, Hamerman JA, Speake C, Malhotra U, Wurfel MM, Ziegler S, Mikacenic C
    • Dec 2021

      Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals.

      PLoS Pathog
      Johansson AM, Malhotra U, Kim YG, Gomez R, Krist MP, Wald A, Koelle DM, Kwok WW
    • Aug 2021

      Endomembrane targeting of human OAS1 p46 augments antiviral activity.

      Elife
      Soveg FW, Schwerk J, Gokhale NS, Cerosaletti K, Smith JR, Pairo-Castineira E, Kell AM, Forero A, Zaver SA, Esser-Nobis K, Roby JA, Hsiang TY, Ozarkar S, Clingan JM, McAnarney ET, Stone AE, Malhotra U, Speake C, Perez J, Balu C, Allenspach EJ, Hyde JL, Menachery VD, Sarkar SN, Woodward JJ, Stetson DB, Baillie JK, Buckner JH, Gale M Jr, Savan R
    • Apr 2021

      Early Prognostic Indicators of Subsequent Hospitalization in Patients with Mild COVID-19.

      J Clin Med
      Ylescupidez A, Rips A, Bahnson HT, Speake C, Verma P, Hocking AM, Buckner JH, Malhotra U
    • Feb 2021

      The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity.

      J Clin Invest
      Bolouri H, Speake C, Skibinski D, Long SA, Hocking AM, Campbell DJ, Hamerman JA, Malhotra U, Buckner JH, Benaroya Research Institute COVID-19 Research Team.
    • Sep 2020

      Ontogeny of different subsets of yellow fever virus-specific circulatory CXCR5+ CD4+ T cells after yellow fever vaccination.

      Sci Rep
      DeGottardi Q, Gates TJ, Yang J, James EA, Malhotra U, Chow IT, Simoni Y, Fehlings M, Newell EW, DeBerg HA, Kwok WW
    • Jan 2016

      Neuroinvasive West Nile Infection Elicits Elevated and Atypically Polarized T Cell Responses That Promote a Pathogenic Outcome.

      PLoS Pathog
      James EA, Gates TJ, LaFond RE, Yamamoto S, Ni C, Mai D, Gersuk VH, O'Brien K, Nguyen QA, Zeitner B, Lanteri MC, Norris PJ, Chaussabel D, Malhotra U, Kwok WW
    • Dec 2013

      Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.

      J Virol
      James EA, LaFond RE, Gates TJ, Mai DT, Malhotra U, Kwok WW
Benaroya Research Institute

1201 Ninth Avenue
Seattle, WA 98101-2795
(206) 342-6500

facebook Bluesky instagram linkedin youtube threads
Resources
  • Support our Research
  • Subscribe to News
  • Careers
  • Contact Us
  • Research Conflicts of Interest
  • Research Security Program
  • Terms of Use
  • Research Requirements
If you would like to contact us regarding the accessibility of our website, please contact us at 206-342-6500 or email communications@benaroyaresearch.org.
© 2025 Benaroya Research Institute, a 501(c)(3) nonprofit organization
Close Close